Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness?
- If you are wondering whether Danaher is starting to look attractively priced or still has more room to fall, its recent share performance and valuation checklist provide a useful starting point.
- The stock last closed at US$198.80, with returns of a 3.5% decline over 7 days, 8.2% decline over 30 days, 13.7% decline year to date, 2.5% decline over 1 year, 5.3% decline over 3 years, and a 5.6% gain over 5 years.
- Recent coverage has focused on Danaher as a large US healthcare and life sciences group that sits at the crossroads of diagnostics, scientific research tools, and biopharma services. This positioning can influence how investors think about its long-term role in healthcare. Commentary has also highlighted how broader sentiment…
Source link
